Compositions and methods for transplantation of colon microbiota
The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
1. A method of increasing the relative abundance of one or more members of the phylum Firmicutes in a patient in need thereof, the method comprising:
administering to said patient an effective amount of a pharmaceutical composition comprising a human fecal microbe preparation comprising a pharmaceutically acceptable carrier and a human fecal extract comprising a healthy human fecal donor's intestinal microbiota comprising at least 6 different classes of bacteria selected from the group consisting of Actinobacteria, Bacteroidia, Bacilli, Clostridia, Erysipelotrichi, Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Mollicutes, and Verrucomicrobiae,
wherein said human fecal extract comprises particles of nonliving material and particles of biological material, and said human fecal extract comprises no particle having a size of greater than 0.5 mm, and
wherein the administering increases the relative abundance of total members of the phylum Firmicutes by at least 20% compared to before said administering.
2. The method of claim 1 , wherein said administering increases the relative abundance of one or more members of the phylum Firmicutes by at least 20% compared to before said administering.
3. The method of claim 2 , wherein said one or more members of the phylum Firmicutes are one or more non-pathogenic members of the class Clostridia.
4. The method of claim 3 , wherein the relative abundance of said one or more non-pathogenic members of the class Clostridia is increased by at least 20% compared to before said administering.
5. The method of claim 1 , wherein the relative abundance is determined at a time selected from the group consisting of 3 days after said administering, 10 days after said administering, 15 days after said administering, and 25 days after said administering.
6. The method of claim 1 , wherein said administering is orally administering.
7. The method of claim 1 , further comprising pretreating said patient with one or more antibiotics prior to said administering.
8. The method of claim 7 , wherein said one or more antibiotics are selected from the group consisting of Metronidazole, Rifaximin, Vancomycin, and Neomycin.
9. The method of claim 1 , wherein said human fecal donor is unrelated to said patient.
10. The method of claim 1 , wherein said human fecal preparation consists essentially of particles capable of passing through a 0.5 mm sieve and the human fecal donor's intestinal microbiota.
11. The method of claim 1 , wherein said pharmaceutical composition is frozen.
12. The method of claim 1 , wherein said effective amount of said pharmaceutical composition comprises at least 5×10 10 cells.
13. The method of claim 1 , wherein said patient has a Clostridium difficile infection.
14. The method of claim 13 , wherein said administering also increases the fecal microbiota diversity in said patient compared to before said administering.
15. The method of claim 1 , wherein said patient has a recurrent Clostridium difficile infection.
16. The method of claim 1 , wherein said patient is at risk of developing a recurrent Clostridium difficile infection.
17. The method of claim 1 , wherein said patient has an inflammatory bowel disease.
18. The method of claim 1 , wherein said pharmaceutical composition is contained within a capsule.
19. The method of claim 1 , wherein said administering is rectally administering.
20. The method of claim 1 , wherein said pharmaceutical composition is lyophilized.